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A B S T R A C T
Background: JZP-110 is a wake-promoting agent with dopaminergic and noradrenergic activity.
Methods: This double-blind, crossover study, randomized adults with narcolepsy with or without cata-
plexy (N = 33) to placebo or JZP-110 at 150 mg/day (weeks 1 and 3) increased to 300 mg/day (weeks 2
and 4). Patients had to have baseline Epworth Sleepiness Scale (ESS) scores ≥10 and mean sleep laten-
cies ≤10 min on the Maintenance of Wakefulness Test (MWT). Eﬃcacy end points included MWT sleep
latency and ESS, and the percentage of patients improved on the Clinical Global Impression of Change.
Results: Patients were primarily male (57.6%) and white (69.7%), with a mean (standard deviation) age
of 37.1 (12.4) years. At two weeks, the change in the mean MWT sleep latency was 11.8 min longer with
JZP-110 than with placebo (P = 0.0002); JZP-110 resulted in greater changes in sleep latency on each MWT
trial (P < 0.001). For ESS, JZP-110 was more eﬃcacious relative to placebo after 1 (P < 0.0001) and two
weeks (P = 0.0002); ﬁnal ESS scores were 10.8 with JZP-110 and 15.2 with placebo, changes of −6.7 and
−2.4, respectively. JZP-110 was generally well tolerated; the most common adverse events with JZP-110
were nausea (12%), noncardiac chest discomfort (9.1%), and headache (9.1%).
Conclusions: The eﬃcacy of JZP-110 for impaired wakefulness and excessive sleepiness was observed at
150–300mg/day and as early as oneweek after initiating treatment (Clinicaltrials.gov identiﬁer NCT01485770).
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Narcolepsy is a chronic, debilitating neurological disorder with an
early onset, generally by the second decade of life [1,2], that tends to
be under-recognized and underdiagnosed [3]. The prevalence of nar-
colepsy is low, 0.05% in the United States [4] and from 0.02% to 0.05%
inmost countries in theworld,with extremes in Japan (0.16%) and Israel
(0.002%) [5,6]. Narcolepsy is associatedwith substantial patient and eco-
nomic burdens resulting from reductions in function and quality of life
as well as higher health-care resource utilization and costs relative to
those without narcolepsy [7–9].
Narcolepsy is characterized by a pentad of symptoms that include
excessive sleepiness, cataplexy, sleep paralysis, hypnagogic hallu-
cinations, and disrupted nighttime sleep. Excessive sleepiness,
although not unique to narcolepsy, is present in all patients, and it
is an essential component of both the International Classiﬁcation of
Sleep Disorders, Third Edition, and the Diagnostic and Statistical Manual
of Mental Disorders, Fifth Edition [10,11] diagnostic criteria. It is often
the ﬁrst presenting symptom at narcolepsy onset [12].
The treatment of narcolepsy focuses on alleviating symptoms as
there is currently no cure. Published treatment recommendations
reﬂect practice parameters, society guidelines, and evidence-
based review [13–15]. In the United States, these recommendations
include drugs that have been approved by the United States Food
and Drug Administration for narcolepsy either as a general condi-
tion (ie, stimulants such as Dexedrine [dextroamphetamine] and
Ritalin [methylphenidate]), to improve wakefulness in adult pa-
tientswith excessive sleepiness associatedwithnarcolepsy (ie,wake-
promoting agents such as Provigil [modaﬁnil; Teva Pharmaceuticals,
Frazer, PA, USA] and Nuvigil [armodaﬁnil; Teva Pharmaceuticals,
Frazer, PA, USA]), or for the treatment of excessive daytime sleepiness
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and cataplexy in narcolepsy (Xyrem [sodium oxybate; Jazz Phar-
maceuticals Inc., Palo Alto, CA, USA]). In the European Union, drugs
approved for narcolepsy by the EuropeanMedicines Agency include
modaﬁnil, sodium oxybate, and immediate release methylpheni-
date. These published recommendations also include other drugs
that have lower levels of evidence and that are used for narcolepsy
off-label for cataplexy (eg, tricyclic antidepressants, selective sero-
tonin reuptake inhibitors, venlafaxine, and reboxetine) [13–15]. In
addition to treatment recommendations, practical considerations
for patient management in the clinical setting have also been pub-
lished [16,17]. However, despite this guidance,management remains
challenging because some drugs may not be appropriate for par-
ticular patients, and patients may not necessarily respond to a
particular drug or to any drug currently available, or it may have
issues of tolerability. In particular, excessive sleepiness and the in-
ability to maintain wakefulness are reported by patients as having
a great impact on daily function [18]. Patients also report that they
have diﬃculty in balancing the beneﬁts and risks of therapies, some
of which may result in intolerable side effects, have complex med-
ication regimens, or result in increased tolerance over time [18].
Consequently, there remains a need for new therapeutic options.
JZP-110 ([R]-2-amino-3-phenylpropylcarbamate hydrochlo-
ride; formerly known as ADX-N05), is a phenylalanine derivative
and an atypical wake-promoting drug with a mechanism of action
that differs from traditional stimulants such as dextroamphet-
amine and wake-promoting agents such as modaﬁnil [19]. JZP-
110 indirectly enhances dopaminergic and noradrenergic
neurotransmission [19], and it does not inhibit serotonin reuptake,
release monoamines, or inhibit monoamine oxidase A (MAO-A) en-
zymatic activity [20].
In nonclinical studies, JZP-110 has been shown to have robust
wake-promoting effects without producing pronounced increases
in locomotor activity [19]. These effects were in contrast to those
of dextroamphetamine, which also delayed sleep onset, but pro-
duced pronounced hyperactivity and stereotypic movements [20].
Another observed difference between JZP-110 and dextroamphet-
amine in preclinical studies was that animals treated with JZP-
110 exhibited the recovery of rapid eye movement (REM) and non-
REM sleep without rebound hypersomnia, whereas animals treated
with dextroamphetamine exhibited overcompensation of non-
REM and REM sleep (ie, rebound hypersomnia) [20,21].
The above observations suggest that JZP-110 may have thera-
peutic potential for the treatment of excessive sleepiness and
impaired wakefulness in narcolepsy. This article presents the results
of a proof-of-concept study evaluating the eﬃcacy and safety of oral
administration of JZP-110 in adults with narcolepsy.
2. Methods
2.1. Study design
This was a randomized, double-blind, placebo-controlled trial
of crossover design that consisted of a 2-week treatment with JZP-
110 or with placebo followed by immediate crossover to the other
treatment (Clinicaltrials.gov identiﬁer NCT01485770). Patients were
randomized to one of the two treatment sequences, that is, placebo
followed by JZP-110 or the converse sequence (Fig. 1). The study
was performed in accordance with the Declaration of Helsinki, and
all patients provided written informed consent prior to participa-
tion. The study protocol, all protocol amendments, and the informed
consent form were reviewed and approved by the central institu-
tional review board prior to study initiation.
2.2. Patients
Adults between 18 and 65 years of age with a diagnosis of nar-
colepsy with or without cataplexy, deﬁned by the second edition
of the International Classiﬁcation of Sleep Disorders, were included
in the study [22]. Patients also were required to have a baseline score
of ≥10 on the Epworth Sleepiness Scale (ESS) [23] and a baseline
sleep latency of ≤10 min for the average of a four-trial Mainte-
nance of Wakefulness Test (MWT), which was performed the day
following an overnight stay at the study site.
Participants were excluded if they had a history of signiﬁcant
cardiovascular disease; a medical disorder, other than narcolepsy,
that was associated with excessive sleepiness; a history of phenyl-
ketonuria or hypersensitivity to phenylalanine-derived products; a
body mass index >34; a nicotine dependence that has an effect on
sleep; or a history of alcohol or drug abuse within the past two years.
Participants were also excluded if they reported excessive caffeine
use one week prior to study; the use of any product with stimu-
lating or sedating properties, selective serotonin reuptake inhibitors,
or anticonvulsant agents within 14 days prior to dosing; or any in-
vestigational drug use within 30 days prior to dosing. Women who
were pregnant or lactating were also excluded. Prior use of medi-
cations for the treatment of narcolepsy including any over-the-
counter sleep aids or stimulants was allowed provided the last use
was aminimum of ﬁve half-lives of the drug(s) in question; for those
previously using sodium oxybate, a return to baseline level of ex-
cessive sleepiness was required for enrollment. At the time of
screening, ﬁve patients were taking modaﬁnil or armodaﬁnil, ﬁve
patients were taking an amphetamine ormethamphetamine product,
two patients were taking sodium oxybate, and one patient was taking
an antidepressant (ﬂuoxetine) for narcolepsy symptoms.
2.3. Treatment
Patients were randomized in a 1:1 ratio to one of two treat-
ment sequences that included two weeks of placebo, immediately
followed by crossover to twoweeks of JZP-110 treatment or the con-
verse sequence. During JZP-110 treatment, the drug was
administered at a dose of 150 mg/day during the ﬁrst week, and it
was increased to 300 mg/day for the second week, with the doses
reﬂecting the free base of the molecule. Patients were instructed
to take their single daily dose of study medication in the morning
on an empty stomach within 1 h of awakening; breakfast was
allowed after 30 min following dosing. At the end of each treat-
ment week, patients returned to the investigative site to complete
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Fig. 1. Study design. ESS, Epworth Sleepiness Scale; MWT, Maintenance of Wakefulness Test.
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their weekly study visits. On the night prior to the week-2 and
week-4 visits, patients were required to sleep at the investigative
site overnight, and they took their dose of study medication at the
investigative site within 1 h of awakening. Patients who did not tol-
erate week-2 or week-4 dosing were able, at the discretion of the
investigator, to reduce the dose to that received the previous week.
2.4. Outcomes
A four-trial MWT was performed at baseline and on treatment
at the end of weeks 2 and 4, following an overnight stay at the study
site and in accordance with practice parameter recommenda-
tions, but in the absence of overnight polysomnography on the
preceding night [24]. The ﬁrst trial was performed 1 h post dose,
and each trial was of 40-min duration with 2-h intervals between
trials; the 40-min version of the MWT was used as this is recom-
mended for obtaining objective data on the ability to remain awake
[24]. Eﬃcacy was evaluated by determining the change from base-
line in sleep latency on the MWT, with sleep latency deﬁned as the
time from lights out until the ﬁrst of three consecutive epochs of
Stage N1 sleep or 1 epoch of N2, N3, or REM. Reported sleep-
latency time reﬂects the average of the four trials unless noted
otherwise.
Additional eﬃcacy outcomes included the ESS, which was com-
pleted by the patient at baseline and at the weekly study visits
(weeks 1, 2, 3, and 4), and the Clinical Global Impression of Change
(CGI-C), whichwas also completed by the investigator at eachweekly
study visit. The CGI-C consists of a seven-point scale ranging from
“1 = very much improved” to “7 = very much worse.” [25]
Safety assessments were performed at each study visit, and all
adverse events (AEs) reported by the patient, as well as those noted
by the investigator, were recorded. As excessive sleepiness is a
symptom of narcolepsy, it was not considered an AE unless the
patient noted a worsening or if they experienced some other adverse
or unintended alteration of their sleep pattern. The evaluation of
safety also included vital signs, standard laboratory assessments,
and electrocardiograms (ECGs). The occurrence of treatment-
emergent suicidality (ie, ideations or behaviors) was assessed using
the Columbia-Suicide Severity Rating Scale [26] with the “Since Last
Visit” version of the scale.
2.5. Statistical analysis
This study was planned as a proof-of-concept study. Sample size
calculation was based on the difference in the mean change from
baseline in the average sleep latency (in minutes) from the four
MWT trials comparing JZP-110 with placebo. A sample size of 30
patients completing both treatment periods was determined to be
suﬃcient to detect a difference in sleep latency of 3.2 min, given a
pooled standard deviation (SD) of 6.0 min, a power of 80%, and an
alpha of 0.05. The 3.2-min difference was based on studies of other
approved wake-promoting medications, modaﬁnil and armodaﬁnil,
where the average differences of 2.9–4.5 min in sleep latency were
observed between active treatment and control [27–30]. A total
enrollment of 40 adult patients with narcolepsy (20 patients per
treatment sequence) was planned for study participation, based
on the assumption that at least 30 patients would complete the
study.
Eﬃcacy end points included the 2-week change from baseline
in sleep latency on the MWT (average of the four MWT trials) and
ESS, and the percentage of patients who achieved at least minimal
improvement on the CGI-C. The effects of treatment on change from
baseline in sleep latency on theMWTwere evaluated using amixed-
effects analysis of variance (ANOVA) model with treatment, site, and
treatment-by-site interaction effects; visit and visit-treatment in-
teraction terms were also included in the model as the study was
of crossover design. For each of the four individual MWT trials, a
paired t-test was used to compare the active and placebo periods.
Paired t-tests were also used for the evaluation of change from base-
line in ESS. Two-sided tests at the 0.05 level of signiﬁcance (α = 0.05)
were used for all comparisons between treatments. Variance is ex-
pressed as SD in the text, and as standard error (SE) in the ﬁgures
to maintain readability. The effect size for the main outcome of
change from baseline in average sleep latency was estimated post
hoc. Statistical analyses were performed using Statistical Analysis
System (SAS) version 9.2 or later (SAS Institute, Inc., Cary, NC,
USA).
3. Results
3.1. Patient disposition and characteristics
A total of 33 patients were enrolled, and all patients com-
pleted the study. Demographic characteristics (Table 1) show that
the majority of patients were male (57.6%) and white (69.7%), with
a mean (SD) age of 37.1 (12.4) years. The patients also reported sub-
stantial sleepiness at baseline with a mean (SD) ESS score of 17.6
(3.5). Cataplexy was present in approximately half of the patients
(54.6%).
3.2. Eﬃcacy
None of the eﬃcacy assessments showed effects for site,
treatment-by-site interaction, visit, treatment-by-visit interac-
tion, or order effect. The mean (SD) sleep latency on the MWT at
baseline was 5.2 (3.1) min, and after 2 weeks of treatment, the in-
crease from baseline was 12.7 (10.6) min with 300 mg/day JZP-
110 and 0.9 (6.0) min with placebo. The ANOVA model estimate of
the least square (LS)mean difference between treatments of 10.9min
was statistically signiﬁcant favoring JZP-110 (P = 0.0002; Fig. 2A).
The effect size (Cohen’s d) was 1.37. Fig. 2B, which presents the
average sleep-latency times for the four MWT trials for individual
patients by treatment phase, shows that although there were some
patients who had no or small increases in sleep-latency time, most
patients had substantial increases in sleep latency with JZP-110 rel-
ative to placebo; there were seven patients who had an increase
of <3 min on the MWT, and only a few patients either did not have
an increase or had an increase of <1 min.
When MWT sleep latency was evaluated for each trial (Fig. 3),
the mean change from baseline was signiﬁcantly greater with
300 mg/day JZP-110 than with placebo for each of the four trials
Table 1
Demographic and clinical characteristics of the study population (N = 33).
Variable Value
Age, years, mean ± SD 37.1 ± 12.4
Gender, n (%)
Male 19 (57.6)
Female 14 (42.4)
Race, n (%)
Black/African American 10 (30.3)
White 23 (69.7)
Disease duration, years, mean ± SD 9.4 ± 8.9
Cataplexy status, n (%)
With cataplexy 18 (54.6)
Without cataplexy 15 (45.5)
BMI, kg/m2, mean ± SD 26.9 ± 3.6
MWT sleep latency, minutes, mean ± SD* 5.2 ± 3.1
ESS score, mean ± SD 17.6 ± 3.5
* Evaluated as the average of a four-trial Maintenance of Wakefulness Test (MWT).
BMI, body mass index; ESS, Epworth Sleepiness Scale; SD, standard deviation.
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(P ≤ 0.001). Changes ranged from 11 to 14 min with JZP-110 and
changes of −1 to 2 min with placebo.
As shown in Fig. 4, the change from baseline in ESS at week 2
or 4, after 2weeks of treatment with JZP-110 (150mg/day for 1week
followed by 300mg/day for one week), showed signiﬁcantly greater
improvement with JZP-110 relative to placebo (P = 0.0002). Themean
changes were −6.7 (6.2) with JZP-110 and −2.4 (3.8) with placebo,
with ﬁnal ESS scores of 10.8 (6.0) and 15.2 (4.9) with JZP-110 and
placebo, respectively. Results on the CGI-C at two weeks showed
that 75.8% of patients achieved at least minimal improvement when
treated with 300 mg/day JZP-110 compared with 39.4% during
placebo treatment (P = 0.0016; Fig. 5).
Improvements were also observed following one week of treat-
ment on the ESS (Fig. 4) and CGI-C (Fig. 5). The mean (SD) changes
from baseline on the ESSwere −5.3 (5.2) points with JZP-110 150mg/
day compared with −1.2 (4.1) points with placebo (P < 0.0001).
Similarly, at the end of the ﬁrst week of treatment, 87.9% of pa-
tients achieved at least minimal improvement on the CGI-C with
150mg/day, compared with 27.3% with placebo (P < 0.0001). While
on placebo, more than half of the patients remained unchanged from
baseline at both time points, 63.6% at week 1 and 54.5% at week 2,
with a low percentage showing worsening, 9.1% and 6.0% at weeks
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1 and 2, respectively (data not shown). By contrast, no patient was
rated as worse when they were treated with JZP-110. Although the
percentage of JZP-110 patients who were unchanged from base-
line increased from 12.1% at one week to 24.2% at two weeks (data
not shown), there was no signiﬁcant difference in the percentage
of patients treated with JZP-110 who were rated as improved from
weeks 1/3 to weeks 2/4.
3.3. Safety
A total of 32 AEs were reported in 14 patients while on JZP-
110 (42.4%) and 10 AEs in seven patients while on placebo (21.2%;
Table 2). No deaths occurred in the study, and there were no
treatment-emergent serious AEs or discontinuations due to AEs. Most
AEs were mild or moderate in severity. Two severe AEs occurred
with JZP-110, intermittent nausea and insomnia, both of which were
considered related to study drug. Although the intermittent nausea
occurred on the ﬁrst day of treatment with JZP-110 and contin-
ued until the end of treatment, severe insomnia occurred during
treatment with the higher JZP-110 dose (300 mg/day), and it was
resolved by the following day, although the patient continued to
report moderate insomnia during treatment. Themost common AEs,
deﬁned as occurring in ≥2 patients in any treatment group, were
observed only with JZP-110 treatment, and they included insom-
nia (n = 4; 12.1%), nausea (n = 4; 12.1%), chest discomfort (n = 3; 9.1%),
headache (n = 3; 9.1%), anxiety (n = 2; 6.1%), decreased appetite (n = 2;
6.1%), and muscle tightness (n = 2; 6.1%). The three patients who re-
ported the AEs of chest discomfort did not develop any new ECG
changes during the trial, and these events were considered to be
noncardiac by the Medical Monitor, although clear etiologies were
not established. There were no ﬁndings of suicidality on the
Columbia-Suicide Severity Rating Scale during the study, and none
of the reported AEs was suggestive of euphoria.
The 300-mg/day dose was associated with mean (SD) increases
from baseline in systolic blood pressure of 1.1 (8.8) mmHg after treat-
ment. The change in systolic blood pressure with placebo was −3.3
(8.4) mmHg. Themean diastolic blood pressure increased by 0.7 (6.1)
mmHg after treatment with the 300-mg/day dose, whereas placebo
resulted in changes of −1.7 (7.3). The mean changes from baseline
in heart rate were 1.9 (9.3) beats/min with 300 mg/day of JZP-110,
and −1.7 (8.9) beats/min with placebo. The ECG-derived heart rate
also showed an increase of 6 beats/min relative to placebo approx-
imately 2 h after the ﬁnal dose of JZP-110 300mg/day corresponding
to the time to maximum plasma concentration of the drug. There
were no apparent effects on other ECG quantitative parameters in-
cluding PR, QRS, and corrected QTc.
4. Discussion
This study is the ﬁrst to evaluate JZP-110 for the treatment of
impaired wakefulness and excessive sleepiness in patients with nar-
colepsy as assessed by the MWT and ESS, respectively [31–33].
Results showed large and consistent effects across objective and sub-
jective measures at two weeks with JZP-110 300 mg/day that were
statistically signiﬁcant relative to placebo, and the drug was well
tolerated. Signiﬁcant treatment effects were also apparent after one
week of treatment at a lower dose of JZP-110 (150 mg/day).
Sleep latency on theMWT, which objectivelymeasures the ability
to stay awake, was improved by a mean of 11.8 min with JZP-110
relative to placebo. The magnitude of this result is substantial with
an effect size (Cohen’s d) of 1.37, demonstrating a robust effect of
treatment. Although seven patients had an increase on the MWT
of <3 min, which is in the range of what is found with most stimu-
lants and wake-promoting agents, it should be noted that only a
few patients had an increase of <1 min. Furthermore, the signiﬁ-
cant increases in sleep latency for each of the four MWT naps
throughout the day, ranging from 11 to 14 min improvement with
JZP-110, relative to changes ranging from −1 to 2 min with placebo,
demonstrate that the increase in wakefulness associated with JZP-
110 treatment was maintained throughout the 7-h period following
dosing.
Notably, a treatment effect was observed at the ﬁrst eﬃcacy as-
sessment, 1 week after initiating treatment, and it was maintained
at week 2. At the 1-week assessment, patients treated with JZP–
110 at the lower dose of 150 mg/day reported signiﬁcantly greater
improvement in symptoms of daytime sleepiness, based on reduc-
tions in ESS scores, than those treated with placebo. At the second
eﬃcacy assessment, following 1-week of treatment with JZP-110
at 300mg/day, further reductions in subjective sleepiness with JZP-
110 were reported by patients; the ﬁnal average ESS score was 10.8,
which is slightly higher than the range of 0–10 that is generally con-
sidered the normal range [23]. This further decrease in daytime
sleepiness symptoms during week 2 is thought to result from the
higher treatment dose, but it may arise in part from the longer treat-
ment duration. In parallel with the patient-reported results, clinicians
reported a signiﬁcantly greater percentage of patients who achieved
at least the minimum level of improvement on the CGI-C at both
time points, with a high percentage (87.9%) observed after the ﬁrst
week of treatment.
The oral administration of JZP-110 was well tolerated at both
doses, with no serious AEs and no discontinuations due to AEs. The
number of AEs reported and the number of patients who reported
AEs were similar during the ﬁrst and second weeks of treatment
Table 2
Adverse events (AEs).
Adverse event Number of patients (%)
JZP-110 (N = 33) Placebo (N = 33)
150 mg/day 300 mg/day Combined
Number of AEs 17 15 32 10
Patients with AEs 9 (27.3) 7 (21.2) 14 (42.4) 7 (21.2)
Discontinuations due to AE 0 0 0 0
Patients with treatment-related AEs 9 (27.3) 4 (12.1) 11 (33.3) 3 (9.1)
Serious AEs 0 0 0 0
Most common AEs*
Nausea 3 (9.1) 1 (3.0) 4 (12.1) 0
Insomnia 3 (9.1) 1 (3.0) 4 (12.1) 0
Chest discomfort 1 (3.0) 2 (6.1) 3 (9.1) 0
Headache 2 (6.1) 1 (3.0) 3 (9.1) 0
Anxiety 2 (6.1) 1 (3.0) 2 (6.1) 0
Decreased appetite 2 (6.1) 0 2 (6.1) 0
Muscle tightness 0 2 (6.1) 2 (6.1) 0
* Occurring in ≥2 patients in either of the treatment groups.
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with 150 and 300 mg/day JZP-110, respectively, suggesting a lack
of dose-dependent AEs within this dose range. However, the study
design did not allow a valid comparison of relative tolerability of
the two doses. The safety proﬁle was consistent with a previous dose-
ranging study of JZP-110 in 45 patients for the treatment of major
depressive disorder [21]. Although changes in blood pressure and
heart rate were observed, these were transient, and no other ECG
abnormalities were noted.
Several limitations of this study should be noted, including that
it was of short duration and included only a limited number of pa-
tients. The study design did not allow for the direct comparison of
eﬃcacy and tolerability of the 150-mg/day dose versus the
300-mg/day dose. Additionally, neither objective evaluation using
polysomnography of nocturnal sleep nor patient-reported out-
comes of function or quality of life were included in the eﬃcacy
assessments. However, the study was designed as an early phase
proof-of-concept study, and as such, the positive results support
further evaluation of JZP-110 for improvement in wakefulness and
reduction of excessive sleepiness in narcolepsy and other condi-
tions of hypersomnolencewhere there is clinical unmet need. Indeed,
the beneﬁts of JZP-110 suggested by these data have been further
supported by preliminary results from a larger parallel group trial
[34].
In summary, this study, the ﬁrst to evaluate JZP-110 for wake
promotion and reduction of sleepiness in patients with narcolep-
sy, demonstrated that the oral administration of JZP-110 at doses
of 150–300 mg/day was generally well tolerated, and it resulted
in greater improvements relative to placebo on all eﬃcacy
measures, which included an objective measure of wakefulness, a
patient-reported subjective measure of sleepiness, and a global
clinician-reported outcome. The effect size was large, and the onset
of eﬃcacy was observed as early as one week after initiating treat-
ment. More rigorous evaluation is warranted, and the phase 3 studies
that are plannedwill address several of the limitations of the current
study by including a larger patient population, a longer treatment
duration, and the evaluation of additional end points.
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